Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs →
glpzoom
Affiliate disclosure: we earn commission from some partners. Learn more.

Generic name · Weight Loss

Retatrutide

Retatrutide is the active ingredient in Retatrutide.

FDA Boxed Warning (retatrutide class-effect)

Investigational drug. Retatrutide is not FDA-approved and is available only through clinical trials. As a GLP-1-class agent it is expected to carry the class thyroid C-cell tumor warning. Do not purchase 'retatrutide' from any online seller, no legal commercial or compounded supply exists.

Brand names of retatrutide

Currently only one brand markets retatrutide in the US.

  • Retatrutide

    Eli Lilly · Not FDA-approved (compounded/investigational)

    Investigational triple agonist (GLP-1 / GIP / glucagon). Phase 3 weight loss approached ~24%, the highest yet. Not FDA-approved; expected 2027.

    Patient review →Clinical reference →

Primary sources

Aggregated from the FDA prescribing information и pivotal trials for every brand of retatrutide.

  1. [1] Retatrutide Phase 2 in obesity (NEJM, 2023)
  2. [2] TRIUMPH Phase 3 retatrutide program (ClinicalTrials.gov)
  3. [3] Eli Lilly pipeline media resources

Related resources